Jonathan Talamo, MD, chief medical officer at Ocular Therapeutix updated OIS@ASCRS attendees on the clinical progress of Dextenza, which is the subject of an NDA being reviewed by the FDA, and is a treatment for post-surgical pain and inflammation. The company has a PDUFA date of July 19, 2017. He also reviewed the company’s earlier-stage clinical study programs: OTX-DP and OTX-TP for allergic conjunctivitis and glaucoma, respectively. Ocular anticipates launching a Phase I clinical trial of OTX-TIC for glaucoma in the second half of this year.
STAY UP TO DATE WITH OIS
Get the Latest News, Podcasts and Videos.